Poseida Therapeutics (PSTX) Q2 2024 earnings summary

Executive summary

• Advanced partnerships with Roche and Astellas, securing $95 million in milestone and upfront payments in H1 2024.

• Clinical-stage cell therapy and genetic medicines company focused on cancer and rare diseases, leveraging proprietary non-viral gene delivery and gene editing platforms.

• Pipeline includes multiple allogeneic CAR-T programs in clinical trials and genetic medicine candidates in preclinical development.

• Progressed non-viral genetic medicines pipeline, including FDA INTERACT meeting granted for P-FVIII-101.

• No product sales to date; revenue is derived from collaboration and license agreements.

Financial highlights

• Q2 2024 revenue was $26.0 million, up from $20.0 million in Q2 2023, driven by milestone recognition and increased reimbursed R&D under the Roche agreement.

• Net loss for Q2 2024 was $31.4 million, compared to $27.5 million in Q2 2023; net loss for the six months ended June 30, 2024 was $55.65 million, compared to $66.30 million year-over-year.

• Cash, cash equivalents, and short-term investments totaled $237.8 million as of June 30, 2024.

• Research and development expenses rose to $45.5 million in Q2 2024 from $39.2 million in Q2 2023, reflecting increased clinical and preclinical activity.

• General and administrative expenses increased to $12.2 million in Q2 2024, mainly due to a one-time stock-based compensation expense from a CEO succession plan.

Outlook and guidance

• Expects cash runway into the second half of 2025, with potential for further extension from additional milestones and business development.

• Anticipates multiple clinical data updates for P-BCMA-ALLO1, P-MUC1C-ALLO1, and P-CD19CD20-ALLO1 in H2 2024.

• Plans to provide updates on autoimmune disease strategy and host a cell therapy R&D Day in November 2024.

• Long-term funding needs will require additional financing or strategic partnerships.